Callan JMB Inc. Expanded the Company’s compliance-driven logistics platform into the food sampling industryEntered agreement to install oral drug delivery...
Quarter
Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025...
Altimmune, Inc 48-week Data from Phase 2b IMPACT Trial of Pemvidutide in MASH Expected Before Year End End-of-Phase 2 Meeting...
Successfully started 204 patients on IBTROZI™ (taletrectinib) in the third quarter of 2025 Updated data continue to show IBTROZI’s unprecedented...
NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Resolute Holdings Management, Inc. (“Resolute Holdings”) (NYSE: RHLD), an operating management company...
Syndax Pharmaceuticals, Inc. – $45.9 million in total revenue, representing 21% growth over 2Q25 – – $32.0 million Revuforj® (revumenib)...
